Lilly's next-gen obesity drug brings Innovent a phase 3 win in diabetes

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 09, 2024 at 12:02: PM
via Innovent has scored another phase 3 win for mazdutide as the drug showed its superiority to Eli Lilly's diabetes and heart drug Trulicity when it came to glycemic control in patients with Type 2 diabetes.

article source
 

<



Similar threads

cafead
&#039;We&#039;re going to miss the next Keytruda&#039;: Lilly, Merck, Gilead and PhRMA CEOs talk IRA consequences
Replies
0
Views
28
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Lilly&#039;s Mounjaro dose in limited availability in US through next month
Replies
0
Views
135
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Could This Be Eli Lilly&#039;s Next Blockbuster Drug?
Replies
0
Views
160
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Eli Lilly&#039;s $1B buyout bet for Protomer brings the &#039;next frontier&#039; in smart...
Replies
0
Views
112
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Lilly makes waves with next-generation diabetes drug, but GLP-1 rivals needn&#039;t panic:...
Replies
0
Views
137
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote